Emma Verner
About
Emma Verner is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology.
According to data from OpenAlex, Emma Verner has authored 37 papers receiving a total of 221 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Genetics, 18 papers in Pathology and Forensic Medicine and 14 papers in Oncology. Recurrent topics in Emma Verner's work include Chronic Lymphocytic Leukemia Research (19 papers), Lymphoma Diagnosis and Treatment (17 papers) and Acute Lymphoblastic Leukemia research (10 papers). Emma Verner is often cited by papers focused on Chronic Lymphocytic Leukemia Research (19 papers), Lymphoma Diagnosis and Treatment (17 papers) and Acute Lymphoblastic Leukemia research (10 papers). Emma Verner collaborates with scholars based in Australia, New Zealand and United States. Emma Verner's co-authors include Stephen Opat, Constantine S. Tam, David Simpson, James Hilger, Benjamin F. Rush, Judith Trotman, Chan Y. Cheah, Gavin Cull, Jane Huang and Cecily Forsyth and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Haematology.
In The Last Decade
Emma Verner
33 papers receiving 220 citations
Peers
Emma Verner
Márcia Torresan Delamain Brazil
Renata Woroniecka Poland
Claudia Minotto Italy
Laura Maria Fogliatto Brazil
Elena Maino Italy
Silvia Finotto Italy
Silvia Imbergamo Italy
Ana Batlle Spain
Guy Cantin Canada
Silja Mack Germany
Citations per year, relative to Emma Verner Emma Verner (= 1×)
peers
Márcia Torresan Delamain
Countries citing papers authored by Emma Verner
Since
Specialization
Citations
This map shows the geographic impact of Emma Verner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emma Verner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emma Verner more than expected).
Fields of papers citing papers by Emma Verner
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Emma Verner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emma Verner. The network helps show where Emma Verner may publish in the future.
Co-authorship network of co-authors of Emma Verner
This figure shows the co-authorship network connecting the top 25 collaborators of Emma Verner. A scholar is included among the top collaborators of Emma Verner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emma Verner. Emma Verner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Verner, Emma, et al.. (2025). Plasmapheresis as a Bridge to Urgent Thyroidectomy in Severe Amiodarone-Induced Thyrotoxicosis. Cureus. 17(9). e92355–e92355.
2.
Soumerai, Jacob D., Chan Y. Cheah, Mary Ann Anderson, et al.. (2024). Sonrotoclax and Zanubrutinib as Frontline Treatment for CLL Demonstrates High MRD Clearance Rates with Good Tolerability: Data from an Ongoing Phase 1/1b Study BGB-11417-101. Blood. 144(Supplement 1). 1012–1012.
3.
Verner, Emma, Amanda Johnston, Eliza A. Hawkes, et al.. (2024). Ibrutinib plus rituximab and mini-CHOP in older patients with newly diagnosed DLBCL: a phase 2 ALLG study. Blood Advances. 8(21). 5674–5682.
4.
Verner, Emma, Anna Johnston, Eliza A. Hawkes, et al.. (2023). Final analysis of Australasian Leukaemia & Lymphoma Group NHL29: A phase II study of ibrutinib, rituximab and mini‐CHOP in very elderly patients with newly diagnosed DLBCL. Hematological Oncology. 41(S2). 426–427.
5.
Odutola, Michael K., Marina T. van Leeuwen, Fiona Bruinsma, et al.. (2023). Occupational exposure to extremely low-frequency magnetic fields and follicular lymphoma risk: a family case–control study. Occupational and Environmental Medicine. 80(10). 599–602.
6.
Odutola, Michael K., Marina T. van Leeuwen, Julie K. Bassett, et al.. (2023). Dietary intake of animal-based products and likelihood of follicular lymphoma and survival: A population-based family case-control study. Frontiers in Nutrition. 9. 1048301–1048301.
7.
Odutola, Michael K., Marina T. van Leeuwen, Fiona Bruinsma, et al.. (2023). A Population-Based Family Case–Control Study of Sun Exposure and Follicular Lymphoma Risk. Cancer Epidemiology Biomarkers & Prevention. 33(1). 106–116.
8.
Odutola, Michael K., Marina T. van Leeuwen, Jennifer Turner, et al.. (2022). Associations between early-life growth pattern and body size and follicular lymphoma risk and survival: a family-based case-control study. Cancer Epidemiology. 80. 102241–102241.
9.
Fleming, Shaun, John Reynolds, Ashish Bajel, et al.. (2021). Sequential Blinatumomab with Reduced Intensity Chemotherapy in the Treatment of Older Adults with Newly Diagnosed Ph Negative B-Precursor Acute Lymphoblastic Leukemia - Interim Analysis of the Australasian Leukemia and Lymphoma Group ALL08 Study. Blood. 138(Supplement 1). 1234–1234.
10.
Wight, Joel, Nada Hamad, Belinda A. Campbell, et al.. (2021). Diffuse large B‐cell lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance. Internal Medicine Journal. 52(9). 1609–1623.
11.
Verner, Emma, Amanda Johnston, Eliza A. Hawkes, et al.. (2021). Efficacy of Ibrutinib, Rituximab and Mini-CHOP in Very Elderly Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma: Primary Analysis of the Australasian Leukaemia & Lymphoma Group NHL29 Study. Blood. 138(Supplement 1). 304–304.
12.
Cull, Gavin, Jan A. Burger, Stephen Opat, et al.. (2021). Zanubrutinib for treatment‐naïve and relapsed/refractory chronic lymphocytic leukaemia: long‐term follow‐up of the phase I/II AU‐003 study. British Journal of Haematology. 196(5). 1209–1218.
13.
Trotman, Judith, Stephen Opat, Paula Marlton, et al.. (2019). PF481 UPDATED SAFETY AND EFFICACY DATA IN A PHASE 1/2 TRIAL OF PATIENTS WITH WALDENSTRÖM MACROGLOBULINAEMIA (WM) TREATED WITH THE BRUTON TYROSINE KINASE (BTK) INHIBITOR ZANUBRUTINIB (BGB‐3111). HemaSphere. 3(S1). 192–193.
14.
Verner, Emma, Amanda Johnston, Eliza A. Hawkes, et al.. (2019). Response Rates and Quality of Life Outcomes in Australasian Leukaemia & Lymphoma Group NHL29: A Phase II Study of Ibrutinib, Rituximab and Mini-CHOP in Very Elderly Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma. Blood. 134(Supplement_1). 4094–4094.
15.
Othman, Jad, Emma Verner, Constantine S. Tam, et al.. (2018). Severe hemolysis and transfusion reactions after treatment with BGB-3111 and PD-1 antibody for Waldenström macroglobulinemia. Haematologica. 103(5). e223–e225.
16.
Othman, Jad, Emma Verner, Constantine S. Tam, et al.. (2017). Autoimmune hemolytic anemia and hemolytic transfusion reactions in two patients with Waldenstrom macroglobulinemia treated with combination BTK inhibitor and PD-1 inhibitor. Blood. 130. 5153–5153.
17.
Trotman, Judith, Yiu Lam Kwan, Jane Estell, et al.. (2016). Formalising multidisciplinary peer review: developing a haematological malignancy‐specific electronic proforma and standard operating procedure to facilitate procedural efficiency and evidence‐based clinical practice. Internal Medicine Journal. 47(5). 542–548.
18.
Tam, Constantine S., Judith Trotman, Stephen Opat, et al.. (2016). High Major Response Rate, Including Very Good Partial Responses (VGPR), in Patients (pts) with Waldenstrom Macroglobulinemia (WM) Treated with the Highly Specific BTK Inhibitor Bgb-3111: Expansion Phase Results from an Ongoing Phase I Study. Blood. 128(22). 1216–1216.
19.
Verner, Emma, et al.. (2014). Two rare cases of blastic plasmacytoid dendritic cell neoplasm and a literature review. Leukemia & lymphoma. 55(10). 2405–2407.
20.
Verner, Emma, Cecily Forsyth, & Andrew Grigg. (2013). Cyclical thrombocytosis, acquired von Willebrand syndrome and aggressive non-melanoma skin cancers are common in patients with Philadelphia-negative myeloproliferative neoplasms treated with hydroxyurea. Leukemia & lymphoma. 55(5). 1139–1143.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Márcia Torresan Delamain Breakdown of academic impact, for papers by Renata Woroniecka Breakdown of academic impact, for papers by Claudia Minotto Breakdown of academic impact, for papers by Laura Maria Fogliatto Breakdown of academic impact, for papers by Elena Maino Breakdown of academic impact, for papers by Silvia Finotto Breakdown of academic impact, for papers by Silvia Imbergamo Breakdown of academic impact, for papers by Ana Batlle Breakdown of academic impact, for papers by Guy Cantin Breakdown of academic impact, for papers by Silja Mack